Skip to main content

Ciphergen, Biosite in Cardiovascular Biomarker Collaboration

NEW YORK, Feb. 10 - Ciphergen Biosystems and Biosite have begun a collaboration to discover antibody and protein target components for use in diagnostic assays for cardiovascular disease, the companies said today.


Biosite will provide clinical samples that Ciphergen scientists will analyze using its ProteinChip technology. The companies will search for differentially expressed protein biomarkers that may be useful as diagnostics or with therapeutic potential.


Biosite plans to develop antibodies against key biomarkers discovered in this collaboration. Both firms are entitled to royalties from any products successfully developed and commercialized as a result of the research.


The project will initially focus on cardiovascular disease, an area in which Biosite has already commercialized several diagnostic systems.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.